Pathway Genomics Corporation Launches Updated Next Generation Sequencing Tests For Colorectal Cancer

SAN DIEGO--(BUSINESS WIRE)--Pathway Genomics Corporation, a forward-thinking big data healthcare company and global precision medicine clinical laboratory, announced it has launched ColoTrue™, a comprehensive panel that combines next-generation sequencing with deletion/duplication analysis to detect pathogenic variants in 15 high-risk colorectal cancer susceptibility genes. Pathway has also launched a smaller panel, LynchSyndromeTrue™, which tests for Lynch syndrome, the most common form of hereditary colon cancer.

Hey, check out all the engineering jobs. Post your resume today!